

**Table 1.** General characteristics of five patients with Graves' disease after alemtuzumab therapy

Case	Gender & Age (yrs)	EDSS	Prior MS therapy	Other medication	Comorbidities	Interval to onset (months)
1	M/35	3.5	Prednisolone Interferon b-1a Glatirameracetate Amitriptyline	Levetiracetam Tolperison Gabapentin	Arterial hypertension	28
2	F/30	1.5	Prednisolone Plasmapheresis	None	None	38
3	F/34	4	Prednisolone	Citalopram Omeprazol	None	28
4	M/38	2	Prednisolone Interferon b-1a	None	None	23
5	F/47	3	Prednisolone Interferon b-1a	Mirtazapine Zopiclon Gabapentin	Anxiety disorder	44

MS: multiple sclerosis, EDSS: expanded disability status scale.